Robustness of Plasma P-Tau217 Diagnostic Thresholds for Alzheimer Disease Across Various Clinical Populations and Laboratory Environments

BACKGROUND AND OBJECTIVES: Blood-based biomarkers (BBMs), especially plasma tau phosphorylated at threonine 217 (p-tau217), could scale Alzheimer disease (AD) clinical-biological diagnosis, but clinical use requires thresholds transferable across laboratories and populations. We compared Lumipulse p-tau217 with other BBMs; evaluated amyloid-anchored thresholds across centers, analyzers, reagent lots, and clinical populations; and assessed second-line CSF adjudication of gray zone results. METHODS: This multicenter, cross-sectional diagnostic-classification study included an exploratory Brussels cohort and 3 external validation cohorts. Brussels participants were cognitively unimpaired or impaired and had Aβ status determined by amyloid-PET or CSF Aβ42 and tau status by tau-PET or CSF p-tau181. Validation cohorts comprised consecutive Paris memory-clinic patients, patients with early-onset neurodegenerative dementia in Bordeaux, and individuals with monogenic frontotemporal lobar degeneration (FTLD). Plasma p-tau217 was measured locally on Lumipulse analyzers. BBMs and ratios were compared using receiver operating characteristic (ROC) analyses. In Brussels, a Youden cutoff and dual 95% or 97.5% sensitivity/specificity cutoffs were derived; intermediate values defined gray zones. RESULTS: < 0.0001). The 0.193 pg/mL Youden cutoff (95% CI 0.178-0.213) yielded 91.5% sensitivity (95% CI 84.7-95.5) and 91.6% specificity (95% CI 84.8-95.5) and detected neocortical tau-PET positivity with 98.5% sensitivity and 81.8% specificity. In Paris, sensitivity/specificity for clinical-biological AD were 93.2% (95% CI 85.1-97.1)/93.0% (95% CI 81.4-97.6); in Bordeaux, sensitivity/specificity for clinical-biological AD were 95.7% (95% CI 79.0-99.2)/92.3% (95% CI 66.7-98.6). Specificity in monogenic FTLD was 88.4% (95% CI 75.5-94.9). False-positive classifications were enriched in FTLD with amyotrophic lateral sclerosis (ALS). Dual thresholds yielded gray zones in 15.4%-24.8% of Paris patients; second-line CSF testing resolved 86.2%-88.9% of gray zone cases. DISCUSSION: Lumipulse plasma p-tau217 thresholds were transferable across centers, analyzers, reagent lots, and heterogeneous clinical populations, supporting evaluation of plasma-first pathways with confirmatory testing for gray zone values. Values below 0.193 pg/mL made neocortical tauopathy unlikely. Limitations include cross-sectional design, specialized Western European recruitment, unavailable race/ethnicity data, heterogeneous reference standards, incomplete AD copathology adjudication in monogenic FTLD, and no cross-platform comparison.

Authors

Institutions

Publication Details

Journal
Neurology
Published
2026-11-16
DOI
https://doi.org/10.1212/wnl.0000000000218784
Citations
4
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
10.88

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Robustness of Plasma P-Tau217 Diagnostic Thresholds for Alzheimer Disease Across Various Clinical Populations and Laboratory Environments

Lara Huyghe, Jean‐Louis Bayart, Pascal Kienlen‐Campard, Aurélie Bedel et al.
4 citations
Neurology
Dementia and Cognitive Impairment Research
10.88
article

Robustness of Plasma P-Tau217 Diagnostic Thresholds for Alzheimer Disease Across Various Clinical Populations and Laboratory Environments

Lara Huyghe, Jean‐Louis Bayart, Pascal Kienlen‐Campard, Aurélie Bedel, Renaud Lhommel, Adrian Ivanoiu, Nicolas Villain, Thomas Gérard, Hassan Elmazria, Gaëtane Picard, Isabelle Le Ber, Bernard Jimmy Hanseeuw, Lisa Quenon, Yasmine Salman, Lise Colmant, Stéphanie Bombois, Giulia Dingeo, Jonathan Douxfils, Sarra Bahroun, Vincent Planche, Emilien Boyer, Clara David, Foudil Lamari, Richard Lévy, Fabienne Clot, Sophie Auriacombe, Fatimah Nabeebaccus, Emmanuelle Durand
article en
4 citations

Abstract

BACKGROUND AND OBJECTIVES: Blood-based biomarkers (BBMs), especially plasma tau phosphorylated at threonine 217 (p-tau217), could scale Alzheimer disease (AD) clinical-biological diagnosis, but clinical use requires thresholds transferable across laboratories and populations. We compared Lumipulse p-tau217 with other BBMs; evaluated amyloid-anchored thresholds across centers, analyzers, reagent lots, and clinical populations; and assessed second-line CSF adjudication of gray zone results. METHODS: This multicenter, cross-sectional diagnostic-classification study included an exploratory Brussels cohort and 3 external validation cohorts. Brussels participants were cognitively unimpaired or impaired and had Aβ status determined by amyloid-PET or CSF Aβ42 and tau status by tau-PET or CSF p-tau181. Validation cohorts comprised consecutive Paris memory-clinic patients, patients with early-onset neurodegenerative dementia in Bordeaux, and individuals with monogenic frontotemporal lobar degeneration (FTLD). Plasma p-tau217 was measured locally on Lumipulse analyzers. BBMs and ratios were compared using receiver operating characteristic (ROC) analyses. In Brussels, a Youden cutoff and dual 95% or 97.5% sensitivity/specificity cutoffs were derived; intermediate values defined gray zones. RESULTS: < 0.0001). The 0.193 pg/mL Youden cutoff (95% CI 0.178-0.213) yielded 91.5% sensitivity (95% CI 84.7-95.5) and 91.6% specificity (95% CI 84.8-95.5) and detected neocortical tau-PET positivity with 98.5% sensitivity and 81.8% specificity. In Paris, sensitivity/specificity for clinical-biological AD were 93.2% (95% CI 85.1-97.1)/93.0% (95% CI 81.4-97.6); in Bordeaux, sensitivity/specificity for clinical-biological AD were 95.7% (95% CI 79.0-99.2)/92.3% (95% CI 66.7-98.6). Specificity in monogenic FTLD was 88.4% (95% CI 75.5-94.9). False-positive classifications were enriched in FTLD with amyotrophic lateral sclerosis (ALS). Dual thresholds yielded gray zones in 15.4%-24.8% of Paris patients; second-line CSF testing resolved 86.2%-88.9% of gray zone cases. DISCUSSION: Lumipulse plasma p-tau217 thresholds were transferable across centers, analyzers, reagent lots, and heterogeneous clinical populations, supporting evaluation of plasma-first pathways with confirmatory testing for gray zone values. Values below 0.193 pg/mL made neocortical tauopathy unlikely. Limitations include cross-sectional design, specialized Western European recruitment, unavailable race/ethnicity data, heterogeneous reference standards, incomplete AD copathology adjudication in monogenic FTLD, and no cross-platform comparison.

NeurologyVol. 107(11)
Centre National de la Recherche Scientifique (FR), Cliniques Universitaires Saint-Luc (BE), Harvard University (US), University of Namur (BE), Université de Bordeaux (FR), Inserm (FR), Centre Hospitalier Universitaire de Bordeaux (FR), Sorbonne Université (FR), Institut des Maladies Neurodégénératives (FR), Clinique Saint Pierre (BE), Assistance Publique – Hôpitaux de Paris (FR), Pitié-Salpêtrière Hospital (FR), Institut du Cerveau (FR), Namur Research Institute for Life Sciences (BE), BoRdeaux Institute of onCology (FR), UCLouvain (BE), KU Leuven (BE)
Siemens Healthineers, Servier, FONDATION ALZHEIMER
Good health and well-being
Openalex Percentile: Top 2%
Dementia and Cognitive Impairment Research
10.88
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon